EGFR and neoplasm: The mAb depatuximab not only targets the EGFRvIII, but is also able to bind to wild-type EGFR on neoplastic cells with EGFR amplification, even in the absence of EGFRvIII co-mutation, by binding to a tumor-specific, conformationally exposed epitope [32].